No Result
View All Result
  • MISSION STATEMENT
  • CONTACT
  • BE PART OF QUALITY JOURNALISM
  • ARCHIVE
Thursday, October 5, 2023
E-Paper
Kashmir Observer
14 °c
Srinagar
  • NEWSLIVE
    • TOP STORIES
    • LOCAL
    • CITY
    • REGIONAL
    • WORLD
  • IN DEPTH
    • FEATURE
    • HEADS & TAILS
    • OPINION
      • OPINION
      • EDITORIAL
      • KO ANALYSIS
      • LETTERS TO EDITOR
    • SPECIAL REPORT
    • INTERVIEW
    • REVIEW
      • BOOKS
    • LONGFORM
  • BUSINESS
    • BUSINESS NEWS
    • MARKET
    • ENERGY
    • HORTICULTURE
    • HANDICRAFTS
    • CARS & BIKES
    • STARTUP KASHMIR
  • SPORT
    • FOOTBAL
    • CRICKET
    • ADVENTURE SPORTS
    • GOLF
    • ATHLETICS
    • SKIING
    • OTHER SPORTS
  • MEDIA
  • PEOPLE
  • CULTURE
    • KHYEN CHYEN
    • ARTS
    • CRAFTS
    • FESTIVALS
    • THEATER
    • LANGAUGE
  • TRAVEL
    • HOUSEBOATS
    • HOTELS
    • ANGLING
    • CAMPING
    • DESTINATION FOCUS
  • SOCIETY
    • EDUCATION
    • HEADS & TAILS
    • GENDER
    • YOUTH
    • CHILD WELFARE
  • LITERATURE
    • SHORT STORY
    • BOOKS
    • NARRATIVE
  • CINEMA
    • CINEMA & TV
  • ePAPERS
    • BAZAAR OBSERVER
    • YOUNG KASHMIR
    • MIZRAB
  • NEWSLIVE
    • TOP STORIES
    • LOCAL
    • CITY
    • REGIONAL
    • WORLD
  • IN DEPTH
    • FEATURE
    • HEADS & TAILS
    • OPINION
      • OPINION
      • EDITORIAL
      • KO ANALYSIS
      • LETTERS TO EDITOR
    • SPECIAL REPORT
    • INTERVIEW
    • REVIEW
      • BOOKS
    • LONGFORM
  • BUSINESS
    • BUSINESS NEWS
    • MARKET
    • ENERGY
    • HORTICULTURE
    • HANDICRAFTS
    • CARS & BIKES
    • STARTUP KASHMIR
  • SPORT
    • FOOTBAL
    • CRICKET
    • ADVENTURE SPORTS
    • GOLF
    • ATHLETICS
    • SKIING
    • OTHER SPORTS
  • MEDIA
  • PEOPLE
  • CULTURE
    • KHYEN CHYEN
    • ARTS
    • CRAFTS
    • FESTIVALS
    • THEATER
    • LANGAUGE
  • TRAVEL
    • HOUSEBOATS
    • HOTELS
    • ANGLING
    • CAMPING
    • DESTINATION FOCUS
  • SOCIETY
    • EDUCATION
    • HEADS & TAILS
    • GENDER
    • YOUTH
    • CHILD WELFARE
  • LITERATURE
    • SHORT STORY
    • BOOKS
    • NARRATIVE
  • CINEMA
    • CINEMA & TV
  • ePAPERS
    • BAZAAR OBSERVER
    • YOUNG KASHMIR
    • MIZRAB
No Result
View All Result
Kashmir Observer
No Result
View All Result
Home HEALTH

Aspirin To Be Tested As Potential COVID-19 Drug In UK Study

by Agencies
November 6, 2020
A A
2
SHARES
99
VIEWS

London- Painkiller aspirin will be evaluated as a possible treatment for COVID-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.

The scientists behind the RECOVERY trial, which is looking into a range of potential treatments for COVID-19, said it would include the drug, which is commonly used as a blood thinner.

ADVERTISEMENT

“There is a clear rationale for believing that it (aspirin) might be beneficial, and it is safe, inexpensive and widely available,” said Peter Horby, co-chief investigator of the trial.

Patients infected with the coronavirus are at a higher risk of blood clots because of hyper-reactive platelets, the cell fragments that help stop bleeding. Aspirin is an antiplatelet agent and can reduce the risk of clots, the RECOVERY trial’s website said on Friday.

Read Also

Imtiaz Ismail Parray Appointed DIG SSB

Man Chargesheeted For Selling State Land 

At least 2,000 patients are expected to randomly get 150 mg of aspirin daily along with the usual regimen. Data from those patients will be compared with at least 2,000 other patients who receive the standard COVID-19 treatment on its own, the website showed.

Small daily doses of aspirin has been found to reduce the risk of certain cancers. As a blood thinner, it increases the risk of internal bleeding, and taking too much over a long period of time has been associated with kidney damage.

Other treatments being tested in the RECOVERY trial include common antibiotic azithromycin and Regeneron’s antibody cocktail that was used to treat U.S. President Donald Trump’s COVID-19 symptoms.

Unlike Gilead’s remdesivir, which has been approved as a COVID-19 treatment in the United States but has shown poor results in a large World Health Organization trial, aspirin is a generic drug, making it much cheaper.

The RECOVERY trial was the first to show that dexamethasone, a steroid which is also cheap and widely available, could save lives of people severely ill with COVID-19.

It also showed that the anti-malarial drug hydroxychloroquine, once touted by Trump, was of no benefit in treating COVID-19 patients.

 

Follow this link to join our WhatsApp group: Join Now

Be Part of Quality Journalism

Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast.

ACT NOW
MONTHLYRs 100
YEARLYRs 1000
LIFETIMERs 10000

CLICK FOR DETAILS

Share1Tweet1SendShareShareSend
Previous Post

Eco Friendly Constructions Helpful in Covid Era: Dr Hiranandani 

Next Post

New Zealand’s Jacinda Ardern Sworn In For Second Term

Agencies

Agencies

Related Posts

Imtiaz Ismail Parray Appointed DIG SSB
LOCAL

Imtiaz Ismail Parray Appointed DIG SSB

Man Chargesheeted For Selling State Land 
LOCAL

Man Chargesheeted For Selling State Land 

FRI Builds Database Of Chinars To Strengthen Its Conservation Programme
LOCAL

FRI Builds Database Of Chinars To Strengthen Its Conservation Programme

Power Crisis In Kashmir Over, Situation Back To Normal: PDD
TOP STORIES

Power Crisis In Kashmir Over, Situation Back To Normal: PDD

Kargil Records 77.61 Turnout In Hill Council Elections
TOP STORIES

Kargil Records 77.61 Turnout In Hill Council Elections

Youth Shot At, Injured In South Kashmir's Anantnag
TOP STORIES

10th Class Student Shot & Injured in Anantnag

Next Post
New Zealand’s Jacinda Ardern Sworn In For Second Term

New Zealand's Jacinda Ardern Sworn In For Second Term

WHO Sees ‘Explosion’ Of Covid-19 Cases In Europe

WHO Sees ‘Explosion’ Of Covid-19 Cases In Europe

Please login to join discussion

Pages

  • ABOUT US
  • ADVERTISE IN KO
  • ARCHIVE
  • BE PART OF QUALITY JOURNALISM
  • CONTACT
  • CONTRIBUTORS
  • INTERNSHIPS AT OBSERVER
  • JOBS@KO
  • KO – Homepage
  • MISSION STATEMENT
  • POLICIES
    • COMMENTING GUIDELINES
    • COOKIE POLICY
    • DISCLAIMER
    • PRIVACY POLICY
    • TERMS
  • Refund Policy
  • Team

SEARCH IN ARCHIVE

No Result
View All Result

FOLLOW US

About Us

The media in Kashmir, comprising a robust English and vernacular press has a particularly unenviable job to do. The problems faced by it are both universal to the conflict situations and unique to the region. Read More

Advertising

For Advertising on various Kashmir Observer platforms
contact

[email protected]
+91-194-2502327; +91-1947969705

© 1997 -2023 | KASHMIR OBSERVER LLP

No Result
View All Result
  • NEWS
    • TOP STORIES
    • LOCAL
    • CITY
    • REGIONAL
    • WORLD
  • IN DEPTH
    • FEATURE
    • HEADS & TAILS
    • OPINION
      • OPINION
      • EDITORIAL
      • KO ANALYSIS
      • LETTERS TO EDITOR
    • SPECIAL REPORT
    • INTERVIEW
    • REVIEW
      • BOOKS
    • LONGFORM
  • BUSINESS
    • BUSINESS NEWS
    • MARKET
    • ENERGY
    • HORTICULTURE
    • HANDICRAFTS
    • CARS & BIKES
    • STARTUP KASHMIR
  • SPORT
    • FOOTBAL
    • CRICKET
    • ADVENTURE SPORTS
    • GOLF
    • ATHLETICS
    • SKIING
    • OTHER SPORTS
  • MEDIA
  • PEOPLE
  • CULTURE
    • KHYEN CHYEN
    • ARTS
    • CRAFTS
    • FESTIVALS
    • THEATER
    • LANGAUGE
  • TRAVEL
    • HOUSEBOATS
    • HOTELS
    • ANGLING
    • CAMPING
    • DESTINATION FOCUS
  • SOCIETY
    • EDUCATION
    • HEADS & TAILS
    • GENDER
    • YOUTH
    • CHILD WELFARE
  • LITERATURE
    • SHORT STORY
    • BOOKS
    • NARRATIVE
  • CINEMA
    • CINEMA & TV
  • ePAPERS
    • BAZAAR OBSERVER
    • YOUNG KASHMIR
    • MIZRAB

© 1997 -2023 | KASHMIR OBSERVER LLP